title: Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy.
abstract: Objectives. Serum cystatin C seems to be an accurate marker of glomerular filtration rate (GFR) compared to serum creatinine. The aim of this work was to explore the possibility of using serum cystatin C instead of serum creatinine to early predict renal failure in cancer patients who received platinum based chemotherapy.Design and Methods. Serum creatinine, serum cystatin C concentrations, and GFR were determined simultaneously in 52 cancer patients received carboplatin-based or cisplatin-based chemotherapy. Serum creatinine was assayed on Cobas C6000-Roche, serum cystatin C assay was performed on AIA 360-Tosoh, and GFR was determined in all patients, before the first cycle of chemotherapy and before the subsequent administrations.Results. In the overall series, for the prediction of a fall of GFR < 80 mL/min/1.73 m2, the AUC of the ROC curve for cystatin C was 0,667 and the best threshold was 1.135 mg/L (sensitivity 90.5%, specificity 61.1%). For a GFR fall < 60 mL/min/1.73 m2, the AUC of ROC curve for cystatin C was 74.3% and the best threshold was 1.415 mg/L (sensitivity 66.7%, specificity 73.2%).Conclusions. Baseline cystatin C values were not able to predict renal failure during subsequent treatment. In conclusion, serum cystatin C is not a reliable early marker to efficiently predict renal failure in patients receiving chemotherapy.
authors.affiliation: Laboratory Medicine Unit, Department of Diagnostic Pathology and Laboratory, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Naples, Italy.
authors.forename: Ernesta
authors.identifier: 0000-0001-6302-1579
authors.initials: E
authors.lastname: Cavalcanti
authors.affiliation: Laboratory Medicine Unit, Department of Diagnostic Pathology and Laboratory, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Naples, Italy.
authors.forename: Vittoria
authors.initials: V
authors.lastname: Barchiesi
authors.affiliation: Laboratory Medicine Unit, Department of Diagnostic Pathology and Laboratory, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Naples, Italy.
authors.forename: Dionigio
authors.initials: D
authors.lastname: Cerasuolo
authors.affiliation: Laboratory Medicine Unit, Department of Diagnostic Pathology and Laboratory, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Naples, Italy.
authors.forename: Flaviano
authors.initials: F
authors.lastname: Di Paola
authors.affiliation: Laboratory Medicine Unit, Department of Diagnostic Pathology and Laboratory, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Naples, Italy.
authors.forename: Monica
authors.initials: M
authors.lastname: Cantile
authors.affiliation: Uroginecologic Department, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Naples, Italy.
authors.forename: Sabrina Chiara
authors.initials: SC
authors.lastname: Cecere
authors.affiliation: Uroginecologic Department, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Naples, Italy.
authors.forename: Sandro
authors.initials: S
authors.lastname: Pignata
authors.affiliation: Thoraco-Pulmonary Medical Oncology Unit, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Naples, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Morabito
authors.affiliation: Thoraco-Pulmonary Medical Oncology Unit, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Naples, Italy.
authors.forename: Raffaele
authors.initials: R
authors.lastname: Costanzo
authors.affiliation: Clinical Trials Unit, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Naples, Italy; Department of Oncology, University of Turin, AOU San Luigi Gonzaga, Orbassano, Italy.
authors.forename: Massimo
authors.initials: M
authors.lastname: Di Maio
authors.affiliation: Clinical Trials Unit, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Naples, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Perrone
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003404:Creatinine / Q000097:blood; D055316:Cystatin C / Q000097:blood*; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D011379:Prognosis; D051437:Renal Insufficiency / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis; D012680:Sensitivity and Specificity
chemical_list: D015415:Biomarkers; D055316:Cystatin C; D003404:Creatinine; D016190:Carboplatin; D002945:Cisplatin